Evidence is now building for psychedelics' safety and efficacy in treating a range of psychiatric disorders including addiction.

Our results support the assertion that psilocybin increases the malleability of self-related processing, and diminishes shame-based and self-critical thought patterns while improving affect regulation and reducing alcohol cravings. These findings suggest that psychosocial treatments that integrate self-compassion training with psychedelic therapy may serve as a useful tool for enhancing psychological outcomes in the treatment of AUD.

Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base.

These studies provide insights into the interactions between classic psychedelics and a range of drugs, including antidepressants, antipsychotics, anxiolytics, mood stabilisers, recreational drugs and others.

The increasing popularity of psychedelic-assisted psychotherapy (PAP) has generated important discussions about the safety of psychedelic drugs.

The results indicate that any differences in the pharmacological profiles of mescaline, LSD, and psilocybin do not translate into relevant differences in the subjective experience.

Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences.

Participants reported substantial changes, with 43.8% (n = 651/1488) decreasing or ceasing alcohol use, 42.5% (n = 272/640) ceasing or decreasing antidepressant use, and 42.4% (n = 200/471) decreasing or ceasing cocaine use.

Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis.

The intention of this commentary is to articulate the deep synergies between hospice and palliative care and PAT.

The protocol included both an imaginary exposure exercise and a classic exposure therapy in an elevator during the psilocybin-assisted psychotherapy.

Our study found that the rapid effects of ketamine can be made more enduring with simple, portable, digital techniques.

This review covers the latest advances ... utilizing this class of compounds as emerging therapeutics.

Most scales revealed a sigmoid-like increase of effects, with a plateauing at around 100 μg.

Late last week, Oregon Health Authority announced that it has issued the first psilocybin service centre licence.